1️⃣ Intellia just made in vivo CRISPR look registrational
Intellia’s Phase 3 HAELO trial hit its primary and all key secondary endpoints on April 27: one-time lonvo-z cut hereditary angioedema attacks 87% versus placebo in 80 patients, and the company has started a rolling FDA filing.
💡 Why it matters
This is late-stage validation for in vivo gene editing, not another promising Phase 1. It de-risks the platform and puts chronic HAE franchises on a real persistence clock.
☕ Coffee talk
HAE pays on repeat dosing today. How many portfolio models break if one infusion gets through?
2️⃣ Lilly paid before the JAK readout
Lilly agreed on April 27 to buy Ajax Therapeutics for up to $2.3B, picking up phase 1 AJ1-11095, a first-in-class Type II JAK2 inhibitor for myelofibrosis, with first proof-of-concept data due later this year.
💡 Why it matters
Lilly is paying pre-readout again where it thinks mechanism and scarcity can outrun price. If Type II JAK2 holds up better than current drugs, this is a hematology platform move, not a bolt-on.
☕ Coffee talk
Lilly just wrote another pre-readout cheque. How many hematology boards think prices are coming down?
3️⃣ CMS just shortened the device reimbursement gap
CMS and FDA launched RAPID on April 23, a pathway that could bring national Medicare coverage for eligible breakthrough devices as soon as two months after market authorization instead of roughly a year or more.
💡 Why it matters
For medtech, the gap between approval and payment has been part of the financing risk. Compressing that window changes launch timing, bridge-round need and who can back later-stage device companies.
☕ Coffee talk
Two-month Medicare coverage is a different launch model. Which device boards still need a reimbursement bridge?